Abstract
The medical-economic evaluation of lung cancer management, in recent years, unavoidable. The burden of disease constantly increases, with values doubling almost every 10 years. The financial impact will be even greater with the new molecules put on the market (target therapies and check points inhibitors). The methodology of medicoeconomics studies must be adapted to these therapeutic innovations.This work presents the global costs of lung cancer management, the costs by stages (localized, locally advanced and metastatic) and the cost of innovations, especially targeted therapeutics and immunotherapies. A better knowledge of medico-economic studies allows to better understand the market access issues of these new molecules and helps in selecting the most appropriate strategy according to populations managed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
